Glioblastoma, an aggressive cancer in the brain or spinal cord, has proven stubbornly resistant to newer immunotherapies. And radiation and chemotherapy, the standard treatment for glioblastoma, result in fewer than 10% of patients surviving longer than five years after diagnosis.
A new study from Washington University School of Medicine shows that treatment with an immune-boosting protein called interleukin 7 (IL-7) in combination with radiation improves survival in mice with glioblastoma.
Boosting T cells improves survival in mice with glioblastoma – Washington University School of Medicine in St Louis wustl.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wustl.edu Daily Mail and Mail on Sunday newspapers.